The Europe Cell Freezing Media Market would witness market growth of 9.2% CAGR during the forecast period (2023-2030).
The various uses of stem cell therapies are driving the research in the field to search for a cure for many present incurable ailments, further driving the need for freezing cells. For example, young individuals in danger of losing their spermatogonial stem cells (SSC), typically cancer patients, can benefit from testicular tissue cryopreservation and autotransplantation. Both adult and prepubertal testicular tissue can be frozen successfully. As a result, it seems like only a matter of time before successful infertility therapies are available for people.
Similarly, with the use of stem cell therapy, it is now possible to stop the course of neurodegenerative disorders, including Parkinson’s disease, Alzheimer’s disease (AD), and Huntington’s disease, as well as, more crucially, to treat the underlying cause of the condition.
A pan-European association called Myeloma Patients Europe reports that in Europe, myeloma was discovered in about 40,000 persons in 2015 and that by 2025, this figure is expected to nearly triple to 46,000. Since the prevalence of multiple myeloma has been rising in Germany, there is a greater demand for cutting-edge treatments. The German healthcare system’s generous reimbursement rules for cancer treatments are a factor in the market’s expansion. Consequently, the region offers promising potential prospects for extending the market in the coming years due to all of these factors.
The Germany market dominated the Europe Cell Freezing Media Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $18,797.1 Thousands by 2030. The UK market is showcasing a CAGR of 8.3% during (2023 - 2030). Additionally, The France market would display a CAGR of 10% during (2023 - 2030).
Based on Product, the market is segmented into DMSO, Glycerol, and Others. Based on Application, the market is segmented into Stem Cell lines, Cancer Cell Lines, and Others. Based on End-Use, the market is segmented into Pharmaceutical & Biotechnological Companies, Research & Academic Institutes, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., Merck KGaA, Sartorius AG, Bio-Techne Corporation, HiMedia Laboratories Pvt. Ltd., BPS Bioscience, Inc., BioLife Solutions, Inc., PromoCell GmbH, Capricorn Scientific GmbH, and Cell Applications, Inc.
Scope of the Study
Market Segments covered in the Report:
By Product

  • DMSO
  • Glycerol
  • Others


By Application

  • Stem Cell lines
  • Cancer Cell Lines
  • Others


By End-Use

  • Pharmaceutical & Biotechnological Companies
  • Research & Academic Institutes
  • Others


By Country

  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe


Companies Profiled

  • Thermo Fisher Scientific, Inc.
  • Merck KGaA
  • Sartorius AG
  • Bio-Techne Corporation
  • HiMedia Laboratories Pvt. Ltd.
  • BPS Bioscience, Inc.
  • BioLife Solutions, Inc.
  • PromoCell GmbH
  • Capricorn Scientific GmbH
  • Cell Applications, Inc.


Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free